First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
TLXMELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
TLXNEW YORK--(BUSINESS WIRE)---- $TLX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
TLXNEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”) of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Telix securities during the Class Period you may be entitled to compensation without payment of any out of pock
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
TLXPartner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the...
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
TLXMELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.).
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
TLXLOS ANGELES, Jan. 7, 2026 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU SUFFERED A LOSS ON YOUR...
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
TLXLOS ANGELES, Jan. 6, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO...
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
TLXPartner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the...
TELIX PHARMACEUTICALS (NASDAQ: TLX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
TLXPHILADELPHIA, Jan. 5, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the...
TLX Deadline: TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
TLXNEW YORK, Dec. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January...
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
TLXBENSALEM, Pa., Dec. 31, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU ARE AN...
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
TLXMELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to:
TLX Deadline: TLX Investors with Losses in Excess of $100K Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
TLXNEW YORK, Dec. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January...
Levi & Korsinsky Notifies Telix Pharmaceuticals Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline - TLX
TLXNEW YORK, Dec. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix...
TLX Deadline: TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
TLXNEW YORK, Dec. 16, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January...
Telix Pharmaceuticals Ltd. Class Action: Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX
TLXNEW YORK, Dec. 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix...
The Gross Law Firm Notifies Shareholders of Telix Pharmaceuticals Ltd.(TLX) of a Class Action Lawsuit and an Upcoming Deadline
TLXNEW YORK, Dec. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
CLASS ACTION NOTICE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action
TLXPHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the...
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
TLXNEW YORK, Dec. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9,...
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit
TLXPHILADELPHIA, Dec. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the...
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
TLXNEW YORK, Dec. 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9,...
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
TLXSAN FRANCISCO, Dec. 1, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series of regulatory...
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
TLXBENSALEM, Pa., Nov. 19, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU ARE AN...
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
TLXMELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®1, 89Zr-DFO-girentuximab) PET/CT2 would have undergone a change in clinical management, when compared with baseline standard of care (SOC) imaging. The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix, AZ, December 2 – 5, 2025.
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
TLXNEW YORK, Nov. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially...
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
TLX(NASDAQ:TLX) NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially...
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
TLXMELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. ET on Tuesday, September 9, 2025 (2:00 a.m. AEST, Sep 10).
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
TLXLOS ANGELES, Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ: TLX) for violations of the securities laws....
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX
TLXNEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public. So What: If you purchased Telix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen
Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
TLXLOS ANGELES--(BUSINESS WIRE)--Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
TLXLOS ANGELES, Aug. 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ: TLX) for violations of the securities laws....
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
TLXMELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
TLXNEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
TLXTelix Launches Gozellix PSMA-PET Imaging Agent In U.S. For Early, Precise Detection Of Prostate Cancer Metastases
TLXWedbush Initiates Coverage On Telix Pharmaceuticals with Outperform Rating, Announces Price Target of $22
TLXTelix Pharmaceuticals Publishes Fibroblast Activation Protein-Targeting Therapy Candidate In Thyroid Journal
TLXReported Earlier, Telix Gains French Approval For Illuccix, Expanding Access To PSMA-PET Imaging For Prostate Cancer Diagnosis And Management
TLXTelix Pharmaceuticals Reaffirms FY25 Revenue Outlook Of $770M - $800M
TLXTelix Pharmaceuticals Posts Q1 Revenue Increase Of 62% To $186M
TLXTelix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
TLXTelix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.
Reported Earlier, Telix's TLX101 Demonstrates Median Overall Survival Of 12.4 Months In Recurrent High-Grade Glioma Patients
TLXTelix Announces That First Patient Has Been Dosed In First-In-Human ZOLAR Trial Of TLX300-CDx In Advanced Soft Tissue Sarcoma
TLXTelix Says FDA Approved New Drug Application For Gozellix, Its Next-Generation PSMA-PET Imaging Agent For Prostate Cancer
TLXTelix Says Brazilian Health Regulatory Agency ANVISA Has Approved Illuccix Prostate Cancer Imaging Agent
TLXReported Earlier, Telix Achieves First Production Of Lead-212 With New High-Yield, Automated Generator System
TLXReported Earlier, Telix's Kidney Cancer PET Imaging Agent TLX250-CDx Receives FDA Priority Review, Potential 2025 U.S. Launch
TLXTelix Pharmaceuticals Says Biogenix Molecular Research Center In Miami Is Recruiting And Dosing Patients In The ProstACT Global Phase 3 Trial Of Novel Prostate Cancer Radiopharmaceutical
TLXTelix FY24 Total Revenue AU$783.2M, Up 56% From AU$502.5M YoY
TLXTelix Pharmaceuticals Announces Presentations Featuring The Company's Late-stage And Next Generation Therapeutic Programs At The Upcoming American Society Of Clinical Oncology Genitourinary Cancers Symposium To Be Held In San Francisco, Ca (Us) From 13 –
TLX